Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies

被引：14

作者：

Cappuzzo, Federico ^{[1
]}

Soo, Ross ^{[2
]}

Hochmair, Maximilian ^{[3
,4
]}

Schuler, Martin ^{[5
,6
]}

Lam, Kwok Chi ^{[7
]}

Stehle, Gerd ^{[8
]}

Cseh, Agnieszka ^{[9
]}

Lorence, Robert M. ^{[10
]}

Linden, Stephan ^{[11
]}

Forman, Nicole D. ^{[10
]}

Hilbe, Wolfgang ^{[12
]}

Jazieh, Abdul Rahman ^{[13
,14
]}

Tsai, Chun-Ming ^{[15
,16
]}

机构：

[1] Osped Santa Maria Croci, AUSL Romagna, Viale Randi 5, I-48100 Ravenna, Italy

[2] Natl Univ Hlth Syst & Canc Sci, Inst Singapore, Levels 8-10 NUH Med Ctr NUHMC,1 Kent Ridge Rd, Singapore, Singapore

[3] Otto Wagner Spital, Dept Resp & Crit Care Med, Baumgartner Hohe 1, Vienna, Austria

[4] Otto Wagner Spital, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Baumgartner Hohe 1, Vienna, Austria

[5] Univ Duisburg Essen, Univ Hosp Essen, Vest German Canc Ctr, Hufelandstr 55, Essen, Germany

[6] German Canc Consortium DKTK, Partner Site Univ Hosp Essen, Hufelandstr 55, Essen, Germany

[7] Chinese Univ Hong Kong, Prince Wales Hosp, 30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China

[8] Boehringer Ingelheim Pharma GmbH & Co KG, Binger Str 173, Biberach, Germany

[9] Boehringer Ingelheim RCV GmbH & Co KG, Boehringer Gasse 5-11, Vienna, Austria

[10] Boehringer Ingelheim Pharmaceut Inc, 900 Ridgebury Rd, Ridgefield, CT 06877 USA

[11] Boehringer Ingelheim GmbH & Co KG, Binger Str 173, Ingelheim, Germany

[12] Wilhelminenspital Stadt Wien, Dept Internal Med 1, Montleartstr 37, Vienna, Austria

[13] King Saud Bin Abdulaziz Univ Hlth Sci, POB 22490, Riyadh, Saudi Arabia

[14] King Abdullah Int Med Res Ctr, POB 22490, Riyadh, Saudi Arabia

[15] Taipei Vet Gen Hosp, 201,Sec 2,Shih Pai Rd, Taipei, Taiwan

[16] Natl Yang Ming Univ, 201,Sec 2,Shih Pai Rd, Taipei, Taiwan

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 15期

关键词：

afatinib; compassionate use; non-small-cell lung carcinoma; ACQUIRED-RESISTANCE; PHASE-III; BIBW; 2992; CANCER; ERLOTINIB; INHIBITOR; GEFITINIB; TRIAL; ADENOCARCINOMA; DISCONTINUATION;

D O I：

10.2217/fon-2017-0666

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: A global afatinib named patient use program in non-small-cell lung carcinoma (NSCLC) commenced in 2010. Materials & methods: Eligible NSCLC patients had progressed after clinical benefit on prior erlotinib/gefitinib and/or had activating EGFR/HER2 mutations, exhausted all other treatments, and were ineligible for afatinib trials. Results: Data, as of January 2016, were reported on 3966 heavily pretreated NSCLC patients (41 countries; six continents). Among 2595/3966 (65.4%) patients with tumor EGFR status, 2407 (92.8%) were EGFR mutation positive. Median time to treatment failure (2862/3966 [72.2%] patients with available data) was 4.4 months. Among 1141/2862 (39.9%) patients with response reported, objective response rate was 23.4% (267/1141). Safety findings were as expected. Conclusion: Time to treatment failure durations and objective response rates were encouraging.

引用

页码：1477 / 1486

页数：10

共 20 条

[1]

[Anonymous], ANN ONCOL S5

[2] Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies [J].

Campo, Meghan ;

Gerber, David ;

Gainor, Justin F. ;

Heist, Rebecca S. ;

Temel, Jennifer S. ;

Shaw, Alice T. ;

Fidias, Panos ;

Muzikansky, Alona ;

Engelman, Jeffrey A. ;

Sequist, Lecia V. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) :2022-2026

[3] Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design [J].

Chaft, Jamie E. ;

Oxnard, Geoffrey R. ;

Sima, Camelia S. ;

Kris, Mark G. ;

Miller, Vincent A. ;

Riely, Gregory J. .

CLINICAL CANCER RESEARCH, 2011, 17 (19) :6298-6303

[4] Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial [J].

Garassino, Marina Chiara ;

Martelli, Olga ;

Broggini, Massimo ;

Farina, Gabriella ;

Veronese, Silvio ;

Rulli, Eliana ;

Bianchi, Filippo ;

Bettini, Anna ;

Longo, Flavia ;

Moscetti, Luca ;

Tomirotti, Maurizio ;

Marabese, Mirko ;

Ganzinelli, Monica ;

Lauricella, Calogero ;

Labianca, Roberto ;

Floriani, Irene ;

Giaccone, Giuseppe ;

Torri, Valter ;

Scanni, Alberto ;

Marsoni, Silvia .

LANCET ONCOLOGY, 2013, 14 (10) :981-988

[5] LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both [J].

Katakami, Nobuyuki ;

Atagi, Shinji ;

Goto, Koichi ;

Hida, Toyoaki ;

Horai, Takeshi ;

Inoue, Akira ;

Ichinose, Yukito ;

Koboyashi, Kunihiko ;

Takeda, Koji ;

Kiura, Katsuyuki ;

Nishio, Kazuto ;

Seki, Yoko ;

Ebisawa, Ryuichi ;

Shahidi, Mehdi ;

Yamamoto, Nobuyuki .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) :3335-+

[6] Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA) [J].

Kawaguchi, Tomoya ;

Ando, Masahiko ;

Asami, Kazuhiro ;

Okano, Yoshio ;

Fukuda, Masaaki ;

Nakagawa, Hideyuki ;

Ibata, Hidenori ;

Kozuki, Toshiyuki ;

Endo, Takeo ;

Tamura, Atsuhisa ;

Kamimura, Mitsuhiro ;

Sakamoto, Kazuhiro ;

Yoshimi, Michihiro ;

Soejima, Yoshifumi ;

Tomizawa, Yoshio ;

Isa, Shun-ichi ;

Takada, Minoru ;

Saka, Hideo ;

Kubo, Akihito .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18) :1902-1908

[7] Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme [J].

Khan, F. ;

Ottensmeier, C. ;

Popat, S. ;

Dua, D. ;

Dorey, N. ;

Ellis, S. ;

Szabo, M. ;

Upadhyay, S. ;

Califano, R. ;

Chan, S. ;

Lee, L. ;

Ali, C. W. ;

Nicolson, M. ;

Bates, A. T. ;

Button, M. ;

Chaudhuri, A. ;

Mulvenna, P. ;

Shaw, H. M. ;

Danson, S. J. .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (10) :1717-1721

[8] BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models [J].

Li, D. ;

Ambrogio, L. ;

Shimamura, T. ;

Kubo, S. ;

Takahashi, M. ;

Chirieac, L. R. ;

Padera, R. F. ;

Shapiro, G. I. ;

Baum, A. ;

Himmelsbach, F. ;

Rettig, W. J. ;

Meyerson, M. ;

Solca, F. ;

Greulich, H. ;

Wong, K-K .

ONCOGENE, 2008, 27 (34) :4702-4711

[9]

Miller VA, 2010, ANN ONCOL, V21, P1

[10] Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial [J].

Miller, Vincent A. ;

Hirsh, Vera ;

Cadranel, Jacques ;

Chen, Yuh-Min ;

Park, Keunchil ;

Kim, Sang-We ;

Zhou, Caicun ;

Su, Wu-Chou ;

Wang, Mengzhao ;

Sun, Yan ;

Heo, Dae Seog ;

Crino, Lucio ;

Tan, Eng-Huat ;

Chao, Tsu-Yi ;

Shahidi, Mehdi ;

Cong, Xiuyu Julie ;

Lorence, Robert M. ;

Yang, James Chih-Hsin .

LANCET ONCOLOGY, 2012, 13 (05) :528-538

← 1 2 →